Author: admin

  • Pakistan Army actively conducting rescue and relief operations in Punjab – RADIO PAKISTAN

    1. Pakistan Army actively conducting rescue and relief operations in Punjab  RADIO PAKISTAN
    2. Live Updates: Pakistan floods 2025  Dawn
    3. Punjab requests military deployment for flood relief in six districts  The Express Tribune
    4. News stories for Dr Maryam Hafeez  Business Recorder
    5. Khawaja Asif visits Nullah Aik, low lying areas of Sialkot  The Nation (Pakistan )

    Continue Reading

  • Breakthrough 3D Printing Method Creates Record-Setting Superconductors

    Breakthrough 3D Printing Method Creates Record-Setting Superconductors

    In a significant advance for materials science, Cornell University researchers have developed a groundbreaking one-step 3D printing technique that produces superconductors with unprecedented magnetic strength. The innovation could accelerate the development of next-generation technologies, from quantum computers to powerful MRI magnets.

    Superconductors are materials that can conduct electricity with zero resistance when cooled to low temperatures. While their potential is immense, manufacturing complex high-performance superconductors has been a multi-step, resource-intensive process. The Cornell team’s new method simplifies this dramatically.

    The research, led by Professor Ulrich Wiesner and published in Nature Communications, demonstrates a streamlined process using a specialized “superconducting ink.” The ink is made from a blend of copolymers and inorganic nanoparticles that self-assemble during the 3D printing process.

    A final, targeted heat treatment then converts the printed structures into their final, porous crystalline form. The performance of the resulting material is what sets this method apart. When the researchers 3D-printed niobium nitride using this technique, the resulting nanostructured porosity boosted its upper critical magnetic field to a record-setting 40–50 Tesla. This is the highest confinement-induced value ever reported for this compound and represents a major leap in performance.

    “This is a critical step forward,” said Wiesner, the Spencer T. Olin Professor in Cornell’s Department of Materials Science and Engineering. “This one-step process not only simplifies fabrication but also allows for the creation of new, more efficient, and complex superconducting components”.

    Beyond niobium nitride, the research team plans to extend the technique to other superconducting compounds, including titanium nitride. This could unlock a wide range of new applications and lead to more powerful and compact devices across multiple industries.

    The research was conducted at the Cornell High Energy Synchrotron Source, with additional support from the Air Force Research Laboratory.

    Continue Reading

  • Athletics: Diamond League 2025 – all disciplines, all winners

    Athletics: Diamond League 2025 – all disciplines, all winners

    The 2025 Diamond League final takes place in Zurich from 27-28 August, starting with the women’s pole vault competition and ending a day later with the men’s 200m.

    Many of the world’s top track & field stars will compete for glory at the two-day athletics extravaganza, including Olympic men’s 100m champion Noah Lyles, women’s 100m champion Julien Alfred, men’s pole vault world record holder Armand ‘Mondo’ Duplantis and women’s 800m Olympic champion Keely Hodgkinson.

    The first day of competition takes place on the streets of Zurich at Sechseläutenplatz, with athletes in men’s and women’s pole vault, women’s high jump, men’s long jump and men’s and women’s shot put competing for Diamond League titles. Thursday’s action then moves to the Letzigrund Stadium, where 26 more champions will be crowned for the 2025 season.

    The format is simple: the winner in each event during the final will earn the title of 2025 Diamond League champion, with the added bonus of a wild card to September’s World Athletics Championships in Tokyo.

    Read on to discover every winner of the 2025 Diamond League final in Zurich.

    Continue Reading

  • Pakistan slams Israeli strike on Gaza hospital, urges global action

    Pakistan slams Israeli strike on Gaza hospital, urges global action





    Pakistan slams Israeli strike on Gaza hospital, urges global action – Daily Times


































    Continue Reading

  • Xiaomi confirms HyperOS 3 launch event with beta recruitment devices confirmed

    Xiaomi confirms HyperOS 3 launch event with beta recruitment devices confirmed

    Xiaomi is expected to unleash a new generation of flagship dvices next month in China. To recap, the company is believed to have prepared the Xiaomi 16 series with a new Pro Max model along with successors to the Xiaomi 15 and Xiaomi 15 Pro based on Qualcomm’s next Snapdragon 8 Elite silicon. On top of that, evidence suggests that Xiaomi will be announcing Pad 7 and Pad 7 Pro (curr. $599 on Amazon) replacements during the same event.

    In the meantime, Xiaomi has announced HyperOS 3 Beta recruitment. Arriving a few weeks after a leak indicated as much, HyperOS 3 Beta will officially arrive on August 28 at 15:00 local time (07:00 UTC). Nonetheless, the first batch of eligible devices have already been identified:

    • Redmi K80 Pro
    • Redmi K80 Extreme Edition/Redmi K80 Ultra
    • Xiaomi 15
    • Xiaomi 15 Pro
    • Xiaomi 15S Pro
    • Xiaomi 15 Ultra
    • Xiaomi Pad 7 Pro
    • Xiaomi Pad 7s Pro 12.5

    Moreover, Xiaomi has already opened beta program registration on its Chinese-language Xiaomi Community. Allegedly, the company has developed HyperOS 3 based on feedback from over 80,000 users. Presumably, Xiaomi will confirm more details about its next major mobile OS update when it fully announces HyperOS 3 tomorrow.

    Continue Reading

  • Xiaomi’s HyperOS 3 to be announced on August 28

    Xiaomi’s HyperOS 3 to be announced on August 28

    Xiaomi has officially confirmed that its next OS update will be named HyperOS 3, dismissing earlier rumors that suggested it might launch as HyperOS 26. The update will be based on Android 16.

    The Chinese brand revealed in a Weibo post that it will unveil HyperOS 3 on August 28 at an event in China.

    In another post, Xiaomi’s Lu Weibing noted that the upcoming update will improve UI smoothness and responsiveness. We’re not really sure what that means, but all will be revealed tomorrow.

    Meanwhile, Xiaomi will also release the first HyperOS 3 beta immediately after the event to eligible devices. Talking about eligibility, the beta will be first rolled out to the Xiaomi 15 series, Redmi K80 Pro/Ultimate Edition, Pad 7S Pro 12.5, and the Pad 7 Pro in China.

    Interested users can head over to the Xiaomi Community Internal Test center to register.

    Source 1 • Source 2

    Continue Reading

  • World’s first commercial CO2 ‘Graveyard’ opens in Norway

    World’s first commercial CO2 ‘Graveyard’ opens in Norway



    World’s first commercial CO2 ‘Graveyard’ opens in Norway

    The world’s first commercial-scale carbon capture and storage (CCS) “graveyard” has opened in Norway as part of the Northern Lights project.

    Currently, the project is jointly run by Equinor, Shell and Total Energies. It is particularly designed to capture carbon dioxide from industrial sites across Europe.

    Afterwards, make it into the transportation and permanently store it underground to keep it out of the atmosphere.

    The Northern Lights managing director Tim Heijin said in a statement, “We now injected and stored the very first CO2 safely in the reservoir.”

    He further explained, “Our ships facilities and wells are now in operation.”

    In specific terms, captured CO2 is cooled into liquid form and moved to a storage terminal in Oxygarden near Bergen. It is then transferred into large tanks before being injected through a 110-kilometres pipeline into the seabed, at a depth of around 2.6 kilometers for maintaining permanent storage.

    The carbon capture and storage (CCS) technology is listed by the UN and the International Energy Agency for mitigating emissions from sectors like cement and steel.

    World’s first commercial CO2 ‘Graveyard’ opens in Norway

    Meanwhile the initial CO2 will be loaded from the Heidelberg Materials plant in Brevik, Norway.

    The CCS will remain costly due to its potential and various industries are often opting to buy carbon credits instead of paying for storage.

    Northern Lights has signed three contracts in Europe including Netherlands, Denmark’s Orsted biofuel plants and Stockholm Exergi in Sweden.

    The Northern Lights project has the initial capacity of retaining 1.5 million tonnes of CO2 by the Norwegian government and annually plans to increase it to five million tonnes by the end of the decade.

    Continue Reading

  • Nothing busted using professional photos as Phone 3 samples

    Nothing busted using professional photos as Phone 3 samples

    Tech brand Nothing has been caught passing off stock images from professional photographers as samples taken by the Phone 3. Five sample images that Nothing claimed were captured by the device were actually licensed photos taken with other cameras.

    The photographer behind one of the images has anonymously confirmed to The Verge that it wasn’t taken using the Phone 3, and that Nothing had purchased the image license via the Stills stock photo marketplace. The Verge has seen the EXIF file for the anonymous photographer’s image, and can confirm it wasn’t captured using the Phone 3. According to the EXIF data, it was taken in 2023, long before the Phone 3 was released this year.

    Roman Fox, another photographer who captured the car headlight, also confirmed to Android Authority that Nothing had paid for his image, which was taken in 2023 using a Fujifilm XH2s camera. Nothing’s demo samples were accompanied by the message: “Judge for yourself. Here’s what our community has captured with Phone 3.”

    In a statement posted on X, Nothing co-founder Akis Evangelidis says the stock images featured on live demo units were placeholders that should have been updated. Nothing is “actively rectifying” the situation, according to Evangelidis, describing the fakery as “an unfortunate oversight” with “no ill intent.”

    “An initial version of the LDU [live demo unit] needs to be submitted with placeholders around 4 months before launch, to be implemented and tested as we ramp up towards mass production,” said Evangelidis. “Once we enter mass production, those placeholder images are replaced with photo samples through a new version of the LDU, along with final product renders and videos. In this case, it was brought to our attention that some live demo units’ stock imagery were not updated.”

    Licensing photos that were never intended for public use is a little perplexing, especially given that Nothing’s previous process involved using photos that were actually shot using the company’s older phones. This isn’t the first time that a phone company has been caught using fake photography examples, but you would think that Nothing would learn from those mistakes.


    Continue Reading

  • African health ministers call for urgent action as progress against malaria stalls | WHO

    Lusaka – Progress against malaria in the African region has significantly slowed down, with cases declining by just 5% since 2015 and mortality by 16%, far short of the 75% reduction target that was to be achieved by 2025. Without intensified efforts, the region risks missing the 2030 targets under the Global Technical Strategy for malaria.

    The Global Technical Strategy for malaria 2016–2030, adopted in 2015, sets the target of reducing global malaria incidence and mortality rates by at least 90% by 2030.

    Weak health systems characterized by poor and delayed access to quality health services; impacts of conflicts and natural disasters; inadequate domestic financing; and climate change are among the factors hindering progress against malaria. Widespread insecticide resistance; and resistance to diagnostics and antimalarial drugs; as well as insufficient coordination also contribute to the stagnation.

    Few African governments have met their commitments to increase domestic financing to end malaria due to constrained economic environment and conflicting national priorities. In 2023, a total of US$ 4 billion was invested globally in the malaria response, compared with against the US$ 8.3 billion needed. About 63% of malaria funding came from international sources. Recent funding cuts and the global funding shifts could further undermine the gains made so far but present an opportunity for rethinking the financing model of malaria programmes.  

    Meeting for the Seventy-fifth session of the World Health Organization (WHO) Regional Committee for Africa in Lusaka, Zambia from 25 to 27 August 2025, African health ministers called for urgent action to accelerate malaria prevention and control.

    The health ministers agreed on a range of urgent actions including strengthening local institutional capacity to drive health system resilience, training and retaining skilled health workers, including community health workers; strengthening supply chains for malaria commodities through pooled procurement systems and local manufacturing ; improving the use of data analytics to sustain and expand coverage in cost-effective interventions including the roll out of malaria vaccination; as well as increasing domestic funding, coordination and accountability of Governments and stakeholders .

    “Progress has been made, but it is not nearly enough. Cases and deaths are not falling fast enough. We must do more, and we must do it faster,” said Dr Mohamed Janabi, WHO Regional Director for Africa. “Ending malaria is not only about saving lives. It is about unlocking human potential, driving economic growth and securing Africa’s stability and future. Together, governments, partners, civil society and communities can consign malaria to the history books.”

    Over the past two decades, the gains made in malaria control and elimination have led to about 2.2 billion cases and 12.7 million deaths averted thanks to scaled up malaria control efforts.

    There have been increases in the coverage of malaria control measures. Insecticide-treated net use rates increased from 46% in 2021 to 59% in 2023; the number of children accessing seasonal malaria chemoprevention increased from 200 000 in 2012 to 53 million in 2023 across in 18 countries, and by July 2025 close to 6 million children had received malaria vaccines by in 20 countries.

    We are also seeing some progress in malaria elimination, and since 2015, two countries in the Region, Algeria in 2019 and Cabo Verde in 2024, have been certified malaria-free.

    Rwanda and Sao Tome and Principe are on track to meet the 2025 targets, Rwanda for reducing case incidence, and Sao Tome and Principe for lowering mortality, underscoring that tailored, data-driven strategies can deliver lifesaving results.

    With sustained commitment, it is possible to end malaria.

    Continue Reading

  • Viral-Induced Erythema Multiforme Complicated by Secondary Bacterial I

    Viral-Induced Erythema Multiforme Complicated by Secondary Bacterial I

    Introduction

    Erythema multiforme (EM) is a rare skin disease characterized by a variety of lesions, including targetoid plaques. With an annual incidence of less than 1%, it is common in adults under 40 years. The lesions mainly appear on the limbs and are less common on the trunk.1 EM is considered to have a unique etiology, pathophysiology, and clinical course. It is mainly associated with infections, with herpes simplex virus (HSV) being the most common causative agent.2,3 Some drugs and vaccines have also been reported to induce EM.4,5 There are currently no reports of EM occurring after spinal surgery. Postoperative spinal infection is primarily caused by bacteria, with Staphylococcus aureus being the most common pathogen.6 However, due to reduced immune function after surgery, the patients are at a rare risk of viral infection or viral reactivation, and persistent viral infection can easily induce bacterial infection.7,8 We describe a rare case of EM following cervical spine surgery caused by a viral infection and a secondary bacterial superinfection marked with hyperpyrexia. We believe our findings will provide valuable insight into diagnostic and therapeutic strategies in similar cases.

    Case Presentation

    A 59-year-old man who presented with numbness in both upper limbs for more than a month was admitted to our hospital on November 12, 2024. The patient had previously taken vitamin B1, B6, and methylcobalamin for one month without relief of symptoms. Magnetic resonance imaging (MRI) showed multiple ossifications of the posterior longitudinal ligament of the cervical spine, spinal cord compression, and cervical spinal cord deformation (Figure 1). The patient had a history of penicillin allergy but denied any history of viral rash and familial, genetic, neurological, or mental diseases. After admission, the patient had a body temperature of 36.8 °C, white blood cell count (WBC) of 5×109/L, and erythrocyte sedimentation rate (ESR) of 25 mm/h. Based on these findings, he was diagnosed with spondylotic myelopathy and ossification of the posterior longitudinal ligament of the cervical spine.

    Figure 1 Images of the cervical spine. (A) Magnetic resonance, (B) X-ray, and (C) Computed tomography images.

    After ruling out surgical contraindications, the patient underwent single posterior cervical open-door spinal decompression on November 14. During the operation, the left lamina of the cervical vertebrae C2 to C7 were opened to expand the cross-sectional area of the spinal canal, relieve spinal cord compression, and fixed with a micro steel plate. Following the operation, the patient was conscious and had a normal body temperature. However, he had a WBC count of 11.4×109/L and an interleukin 6 (IL-6) level of 22.1 pg/mL. Considering the risk of infection owing to internal fixation, the patient was administered clindamycin (0.6, IVGTT, BID) on November 14. Subsequently, although the surgical incision morphology remained normal, multiple infection indicators gradually increased. On November 21, the following parameters were noted in the patient: WBC count, 11.7×109/L; serum amyloid A (SAA), 59.7 mg/L; C-reactive protein (CRP), 26.1 mg/L; ESR, 42 mm/h. On the morning of November 22, the patient suddenly developed large, itchy red rashes and target-like plaques throughout the body (Figure 2). All medications were discontinued, and he was administered loratadine (10 mg PO, once) and dexamethasone sodium phosphate (5mg, IVGTT, once) for anti-allergic treatment; however, there was no improvement. After consulting dermatologists, viral infection-induced EM was suspected. The viral antigen test of nasal secretions was negative for all types of viral infections. After treatment with ganciclovir (250 mg IVGTT QD) and loratadine (10 mg PO QD), the rash gradually subsided. By November 27, the rash had completely subsided, and ganciclovir and loratadine were discontinued.

    Figure 2 Erythema multiforme lesions. The red mark indicates the typical target lesion of EM.

    However, as the rash began to subside, the patient’s body temperature began to rise again on November 24, 2024. On November 25, he had a body temperature of 38.9 °C, WBC count of 11.6×109/L, SAA 386.9 mg/L, CRP 52.4 mg/L, IL-6 29.3 pg/mL, and ESR 77 mm/h. On November 26, the body temperature further rose to 39.1 °C. Two sets of blood culture samples were collected from each arm that day, with each set comprising both aerobic and anaerobic bacterial cultures. However, no aerobic or anaerobic bacteria were detected in the blood cultures. After consultation with infection experts and clinical pharmacists, secondary bacterial infection was considered, and meropenem (1.0 g IVGTT Q8H) was administered as an anti-infection treatment. On November 28, although the patient’s infection indicators continued to increase, the body temperature dropped. Eventually, the body temperature returned to normal, and the infection indicators also gradually decreased. On December 6, after evaluation by clinical pharmacists, meropenem was discontinued, and moxifloxacin hydrochloride was initiated (0.4 g IVGTT QD) (Figure 3 and Table S1). On December 10, the patient was discharged in stable condition. One month later, the physician confirmed that the patient’s upper limb numbness had subsided, the skin lesions had completely healed, and there were no signs of recurrent infection. The patient experienced no recurrence of fever or rash for six months after discharge.

    Figure 3 Changes in the patient’s body temperature and infection indicators over time The yellow bars indicate surgery, and the red bars indicate abnormal body temperature. The red values are outside the normal range, and the blue squares indicate that medication was used. The red arrow indicates that the indicator has increased compared to the previous measurement, while the blue arrow indicates a decrease. Double red arrows indicate that the indicator has increased fivefold compared to the previous value.

    Discussion

    Spinal surgical site infections (SSIs), especially those occurring after internal fixation, are postoperative complications that require special attention and are often associated with gram-positive bacteria.9 Therefore, after surgery, when the patient showed an abnormal increase in WBC count and IL-6 levels, an infection at the surgical site was suspected, and he was given clindamycin as an empirical antibiotic. However, several factors argued against a typical SSIs: the patient was the first case in the operating room that day, making the possibility of environmental infection low; the surgical incision appeared normal; and, crucially, clindamycin failed to alleviate symptoms or reduce rising infection indicators. The rarity of postoperative viral infection initially delayed consideration of this etiology until the characteristic EM rash emerged. Pathogenic factors that cause EM include infections, drug allergies, and vaccines.10–12 Allergy was systematically excluded: the patient had not received any recent vaccinations, and the rash persisted despite the immediate discontinuation of all medications and the administration of loratadine and dexamethasone. Concurrently, there was no elevation in procalcitonin, a sensitive marker for bacterial infection,13 further ruling out the possibility of a bacterial cause and shifting the focus toward a viral etiology. Nasal secretions and nasopharyngeal swabs were negative for all tested viral infections. HSV is the most common cause of EM.1 Surgery is known to be a precipitating factor for HSV reactivation, and patients with no known history of HSV infection can contract it and develop encephalitis after surgery. This might be caused by the early lack of immunity in postoperative patients. In most (71.4%) previously reported cases of postoperative herpes virus infection, obvious symptoms appeared 2–7 days after surgery. The occurrence, symptoms and postoperative time course of vesicular rash are related to inflammatory response, which is consistent with our patient characteristics. Based on the above evidence, we speculated that the patient had postoperative HSV infection-induced EM. We opted for ganciclovir antiviral treatment instead of escalating the antibiotics, and its effectiveness confirmed our speculation.

    Interestingly, following the resolution of EM and effective antiviral treatment, the patient developed a new episode of hyperpyrexia (peaking at 39.6°C), accompanied by joint pain and myalgia, symptoms atypical for EM.14 Concurrently, previously stable infection indicators, including procalcitonin, rose significantly. This clinical shift suggested a secondary bacterial superinfection. Persistent viral infections can induce bacterial superinfections.15–17 For example, immune-mediated damage caused by the influenza virus leads to the destruction of airway epithelium and its barrier function, induces cytokine production, and disrupts macrophage and regulatory T-cell function, which is believed to promote the colonization of multiple bacteria. In this case, the patient’s postoperative immunocompromised state, combined with extensive EM-related skin barrier disruption on the back, likely created an environment conducive to secondary bacterial invasion. Because the infecting bacteria could not be identified and the patient continued to have a high fever after surgery, the broad-spectrum antibiotic meropenem was administered.18 Subsequently, the fever and systemic symptoms resolved, supporting the diagnosis of bacterial superinfection.

    This is the first reported case of a rare dual infection of virus-induced EM complicated by secondary bacterial infection and hyperpyrexia after cervical spine surgery. A limitation of this study is that the HSV diagnosis was not confirmed because our laboratory does not have the required serological or polymerase chain reaction tests. In addition, because of the low positivity rate of routine blood culture, the nature of the secondary bacterial infection could not be clarified. However, the changes in the patient’s skin manifestations, body temperature, and infection indicators over time, as well as the response to antiviral and antimicrobial treatment, support our speculation.

    Conclusion

    Based on our findings, antimicrobial therapy is recommended for patients with viral infection after cervical spine surgery in the following situations: bacterial infection was not confirmed by the blood cultures obtained, and was suspected by the patients’ course and elevated infection indices. Preventive antiviral treatment before surgery may be beneficial for patients with a history of HSV infection, while for those without such a history, it is necessary to remain vigilant for the activation of latent viruses.

    Abbreviations

    COVID-19, coronavirus disease 2019; CRP, C-reactive protein; EM, erythema multiforme; ESR, erythrocyte sedimentation rate; HSV, herpes simplex virus; IL-6, interleukin 6; MRI, magnetic resonance imaging; SAA, serum amyloid A; WBC, white blood cell count; SSIs, spinal surgical site infections; PO, take orally; QD, once a day; BID, twice a day; Q8H, once every 8 hours; IVGTT, intravenous drip.

    Ethical Approval and Informed Consent

    The study was approved by the Ethics Committee of the Ningbo No.6 Hospital. The patient provided consent for the participate of the study.

    Acknowledgments

    We thank the patient and his parents for participating in this study. We thank all of our et al in the hospital who have been involved in the patient’s care and research. We would like to thank Editage (www.editage.cn) for English language editing.

    Consent for Publication

    The patient gave written informed consent for his personal or clinical details along with any identifying images to be published in this study. The publication of the case details requires approval from the Ethics Committee of Ningbo No.6 Hospital. The approval number was [2025(L)004].

    Funding

    This study was supported by the Ningbo Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation (2024L004).

    Disclosure

    The authors report no conflicts of interest in this work.

    References

    1. Trayes KP, Love G, Studdiford JS. Erythema multiforme: recognition and management. Am Family Physician. 2019;100;(2):82–88

    2. Kechichian E, Dupin N, Wetter DA, Ortonne N, Agbo-Godeau S, Chosidow O. Erythema multiforme. EClinicalMedicine. 2024;77:102909. doi:10.1016/j.eclinm.2024.102909

    3. Shinde SB, Lohe V, Mohod S. Herpes Simplex Virus (HSV)-induced erythema multiforme: a rare case report. Cureus. 2024;16(6):e62650. doi:10.7759/cureus.62650

    4. Sriram S, Jayakanth MJ, Mariam S, Saeed S, Hasan S. Drug-induced oral erythema multiforme: a report of a rare case. Cureus. 2024;16(10):e70977. doi:10.7759/cureus.70977

    5. Wu PC, Huang IH, Wang CW, Chung WH, Chen CB. Erythema multiforme and epidermal necrolysis following COVID-19 vaccines: a systematic review. dermatitis: contact, atopic, occupational. drug. 2025;36(3):188–199. doi:10.1089/derm.2023.0210

    6. Zuo Q, Zhao K, Dong B, et al. Analysis of risk factors for surgical site infection in spinal surgery patients and study of direct economic losses. BMC Musculoskeletal Disorders. 2024;25(1):1096. doi:10.1186/s12891-024-08149-8

    7. Beadling C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis. 2004;17(3):185–191. doi:10.1097/00001432-200406000-00003

    8. Earnhardt EY, Tipper JL, Hanafy MA, et al. ER stress disrupts the airway epithelium and reduces host defense during influenza a virus infection. Am J Respir Cell Mol Biol. 2025. doi:10.1165/rcmb.2025-0141OC

    9. Brodke D, O’Hara N, Devana S, et al. Predictors of deep infection after distal femur fracture: a multicenter study. J of Orthop Trauma. 2023;37(4):161–167. doi:10.1097/bot.0000000000002514

    10. Yan Y, Pan Y, Qu C, Chen Q, Zeng X, Wang J. Rare infection induced recurrent erythema multiforme. Aus Dental J. 2025;(3):190–194. doi:10.1111/adj.13072

    11. Zhu Q, Wang D, Peng D, Xuan X, Zhang G. Erythema multiforme caused by varicella-zoster virus: a case report. SAGE open medical case reports. SAGE Open Med Case Reports. 2022;10:2050313×221127657. doi:10.1177/2050313×221127657

    12. Karatas E, Nazim A, Patel P, et al. Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: a case series. JAAD Case Reports. 2023;32:55–58. doi:10.1016/j.jdcr.2021.12.002

    13. Velissaris D, Zareifopoulos N, Lagadinou M, et al. Procalcitonin and sepsis in the emergency department: an update. Eur Rev Med Pharmacol Sci. 2021;25(1):466–479. doi:10.26355/eurrev_202101_24416

    14. Hernandez quiroz E, Kauffman CL, Kupiec-Banasikowska A. Erythema multiforme following hepatitis a and pneumococcal vaccinations. Yale J Bio Med. 2022;95(2):213–215. doi:10.1016/j.jaad.2019.02.057

    15. Vimalanathan S, Sreya M, Nandanavanam R, et al. Respiratory virus-induced bacterial dysregulation in pediatric airway tissue and the dual actions of Echinacea in reducing complications. Front Pharmacol. 2025;16:1579551. doi:10.3389/fphar.2025.1579551

    16. Hamza YP, Kacem M, Al Molawi NH, et al. Patients in hospital with confirmed bacterial airway infection are significantly more likely to have a respiratory virus co-infection. J Med Microbiol. 2025;74(7). doi:10.1099/jmm.0.001996

    17. Boland H, Endres A, Kinscherf R, et al. Protective effect of interferon type I on barrier function of human airway epithelium during rhinovirus infections in vitro. Sci Rep. 2024;14(1):30510. doi:10.1038/s41598-024-82516-2

    18. Chen H, Zhu C, Yi H, et al. Incidence and management of surgical site infection in the cervical spine following a transoral approach. Int Orthopaedics. 2022;46(10):2329–2337. doi:10.1007/s00264-022-05492-0

    Continue Reading